Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
The regulator gives the nod to the two companies' specialist medication aimed at treating breast cancer.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
The Food and Drug Administration has approved a new type of breast cancer drug developed by ImmunoGen (IMGN +0.00%) and Roche (RHHBY +0.00%), and will be marketed by the latter. The medication, known by the brand name Kadcyla, is used to treat HER 2-positive metastatic breast cancer. It is a combination of Herceptin, an existing Roche drug, with a pair of components developed by ImmunoGen.
HER2 is a protein found on the tumors of roughly 20% to 25% of patients with breast cancer.
The approval will trigger a $10.5 million payment from Roche to ImmunoGen. The latter will also be paid royalties of up to 5% on sales of Kadcyla, which will cost $9,800 per month.
Alert: Top Cash Back Card Now Offers 0% Intro APR Until Nearly 2027
Enjoy 0% intro APR on purchases and balance transfers for 15 months—plus up to 5% cash back in popular categories.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-29 06:51:20.778757.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
